Skip to main content

ACG 2022 Annual Meeting Main banner

Tweets by ACG 2022 Annual Meeting

Browse by Title

Browse by Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

#
52-Week Risankizumab Subcutaneous Maintenance Dosing Is Efficacious and Well Tolerated in Patients With Moderate to Severe Crohn’s Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction (38)

Marla Dubinsky, MD – Icahn School of Medicine ### 1402021###Presenting Author######Icahn School of Medicine###
Presenting Author: Marla Dubinsky, MD – Icahn School of Medicine
### 38